Skip to main content
Subscribe
  • Sign Up Free
  • Login
  • Subscribe
  • News
    • Current News
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Digital Health
    • Transformation
    • ESG
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Blogs
    • AI
    • Deals
    • Layoff Tracker
    • HIMSS 2023
  • Opinion
    • Breaking Bias
    • Commentaries
    • Letters
    • From the Editor
  • Events & Awards
    • Awards
    • Conferences
    • Galas
    • Virtual Briefings
    • Webinars
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • Best Places to Work in Healthcare
    • Excellence in Governance
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top 25 Emerging Leaders
    • Top Innovators
    • Diversity in Healthcare
      • - Luminaries
      • - Top 25 Diversity Leaders
      • - Leaders to Watch
    • Women in Healthcare
      • - Luminaries
      • - Top 25 Women Leaders
      • - Women to Watch
    • Digital Health Transformation Summit
    • ESG: The Implementation Imperative Summit
    • Leadership Symposium
    • Social Determinants of Health Symposium
    • Women Leaders in Healthcare Conference
    • Best Places to Work Awards Gala
    • Health Care Hall of Fame Gala
    • Top 25 Diversity Leaders Gala
    • Top 25 Women Leaders Gala
    • - Hospital of the Future
    • - Value Based Care
    • - Hospital at Home
    • - Workplace of the Future
    • - AI and Digital Health
    • - Future of Staffing
    • - Hospital of the Future (Fall)
  • Multimedia
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Sponsored Video Series - One on One
    • Sponsored Video Series - Checking In with Dan Peres
  • Data & Insights
    • Data & Insights Home
    • Hospital Financials
    • Staffing & Compensation
    • Quality & Safety
    • Mergers & Acquisitions
    • Data Archive
    • Resource Guide: By the Numbers
    • Surveys
    • Data Points
  • Newsletters
  • MORE+
    • Contact Us
    • Advertise
    • Media Kit
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Technology
March 02, 2019 12:00 AM

Why prescription drug list prices matter

Harris Meyer
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print
    Chuck Grassley and Ron Wyden
    AP Photo

    Chairman Sen. Chuck Grassley, right, and ranking member Sen. Ron Wyden confer before a Senate Finance Committee hearing Feb. 26. During the hearing the pair put a spotlight on the importance of high drug list prices.

    Questioning drug company CEOs last week, Sens. Charles Grassley and Ron Wyden hammered away at the importance of high list prices for prescription drugs, while the CEOs testifying before the Senate Finance Committee mostly tried to change the subject.

    But Grassley (R-Iowa) and Wyden (D-Ore.) were right that list prices matter a lot. Medicare Part D drug plan enrollees and a growing number of commercially insured patients pay a percentage of the list price for drugs under their health plans’ coinsurance designs. That amount can be formidable, particularly for costly brand name and specialty products.

    For Part D enrollees who don’t receive low-income subsidies, expected annual out-of-pocket costs in 2019 for 28 common specialty-tier drugs for cancer, hepatitis C, multiple sclerosis and rheumatoid arthritis average $8,109 because of coinsurance, according to the Kaiser Family Foundation. There is no out-of-pocket cap on drug costs for Part D enrollees, including Medicare Advantage plan members.

    In the private sector, most large employer health plans have begun charging enrollees coinsurance rather than flat copayments for prescription drugs, even for generic products, according to benefits consultant Mercer. Smaller employers are likely to follow the larger firms’ lead, Mercer experts say.

    The use of coinsurance is growing not just for prescription drugs but for all healthcare services, as employers and insurers increasingly shift to high-deductible health plans and impose coinsurance rates of 20% or more, rather than flat copays once the deductible is met.

    Some experts say payers are turning to coinsurance to dampen down their costs as they reach the limits of deductible levels acceptable to enrollees. Another attraction is that coinsurance percentages automatically keep pace with price increases, whereas hikes in deductibles and copays are far more visible to enrollees.

    The rationale for using coinsurance is that exposing patients to a percentage of the full price prods them to shift to lower-cost products and services, such as generic drugs. But critics say the growing use of coinsurance worsens affordability problems that have been already exacerbated by the proliferation of high-deductible plans.

    “Coinsurance is one of the more insidious ways employers have been shifting costs to employees,” said Sabrina Corlette, a research professor at Georgetown University’s Health Policy Institute. “Unlike with premiums and deductibles, it’s very difficult for enrollees to know what their costs will be in any given year.”

    From 2006 to 2016, average annual payments by enrollees in large employer plans toward coinsurance rose 67%, while payments toward copays fell 38%, according to the Peterson-Kaiser Health System Tracker. Meanwhile, average payments toward deductibles soared 176%.

    But there is a key difference between coinsurance for medical services and for drugs. For physician and hospital services, patients pay a percentage of the plan’s negotiated price, which is far below the sticker price. For drugs, they generally pay a percentage of the full list price, regardless of rebates received by their plan from the drug manufacturer.

    List prices for the most commonly used brand-name drugs increased 7.3% in 2018, according to Express Scripts.

    Providers say high cost-sharing for prescription drugs discourages patients from taking needed medications, or causes them to take less than the amount prescribed, which is medically risky. 

    “Often a physician will write a prescription they feel is appropriate, and they’ll get a call back from the pharmacist saying the patient can’t afford the medication,” said Dr. Gary LeRoy, president-elect of the American Academy of Family Physicians, who practices at a community health center in Dayton, Ohio. “There’s sticker shock over what they have to pay for some of the newer meds. So you have to search for an alternative.”

    Even the drug company executives testifying Feb. 26 acknowledged this coinsurance affordability issue. “Patients are made to pay on average 14% of the cost of their medicines, but only 3% of the costs associated with hospital stays,” said Albert Bourla, Pfizer’s chief executive. Bourla backed proposals to peg cost-sharing to a drug’s net price with rebates rather than to the list price.

    Enrollees in individual-market health plans have it even tougher, according to a new analysis of silver plans by the Robert Wood Johnson Foundation. In that market, the most common benefit design for the specialty drug tier is offering no coverage until enrollees meet the deductible, after which they must pay 40% coinsurance based on the drug’s list price.

    “The cost-sharing is more rugged than in employer plans,” said Katherine Hempstead, a health insurance analyst at the foundation who did the study. 

    Employer plans with more than 20,000 members are leading the way in establishing hefty coinsurance on brand-name drugs to push employees to use cheaper generic products. Sixty percent applied coinsurance to brand-name drugs through mail-order plans in 2018, while nearly 70% applied coinsurance to these drugs through retail pharmacy plans, according to a Mercer survey. The comparable figures for generic drugs are 34% and 37% respectively.

    “Large employers are slowing increases in deductibles at least partly due to concerns about affordability,” said Beth Umland, who heads research for Mercer. “But increasing coinsurance rather than the deductible won’t address that problem.”

    With no cap on their out-of-pocket drug costs, Medicare beneficiaries are the most vulnerable to stiff coinsurance payments tied to high list prices for medications, despite recent measures to fill in the Part D coverage “donut hole.” Enrollees in most other types of insurance are relatively protected by the Affordable Care Act’s out-of-pocket maximums.

    One million Part D enrollees with out-of-pocket costs above the catastrophic threshold spent more than $3,000 out of pocket on their prescriptions in 2015 due to coinsurance, according to the Kaiser Family Foundation. 

    That’s why Wyden, the Trump administration, and the Medicare Payment Advisory Commission all have proposed capping Part D out-of-pocket spending on drugs, even though that would modestly increase Part D premiums. The administration has proposed putting a $5,000 annual limit on beneficiary drug costs.

    Others, including drugmakers, favor factoring in manufacturer rebates to lower the price on which coinsurance is based, thus reducing how much beneficiaries would pay out of pocket.

    Whatever the approach, many experts argue urgent action is needed to protect Medicare beneficiaries and commercially insured patients as coinsurance payments based on rising list prices for drugs bite into household budgets. 

    “Coinsurance is a mysterious percentage of a mysterious charge,” said Jack Hoadley, a research professor emeritus at Georgetown University. “It would be better if you just set a max of $100 for any given one-month supply of a drug, because otherwise it can cost far more than anyone can afford.”

    Related Story
    Silver health plans set stiffer cost-sharing on drugs than employer plans
    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    doctor_patient_tablet_getty_i_i.jpg
    How AI may influence pain medication prescriptions
    Amir Dan Rubin
    Amazon's One Medical CEO to step down later this year
    Most Popular
    1
    Centene to lay off 2,000 workers
    2
    How health systems are battling price-gouging allegations
    3
    Senate advances bill to temporarily aid hospitals, health centers
    4
    Elevance, Blue Cross Louisiana halt $2.5B proposed deal
    5
    Tower Health to sell urgent care centers, close others
    Sponsored Content
    Digital Health Intelligence Newsletter: Sign up to receive a twice-weekly (T, F) morning newsletter featuring the latest reporting on technologies, trends, players and money fueling the rapid changes in how healthcare is developed, paid for and delivered.
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Help Center
    • Advertise with Us
    • Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2023. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Digital Health
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • ESG
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Blogs
      • AI
      • Deals
      • Layoff Tracker
      • HIMSS 2023
    • Opinion
      • Breaking Bias
      • Commentaries
      • Letters
      • From the Editor
    • Events & Awards
      • Awards
        • Nominate/Eligibility
        • 100 Most Influential People
        • 50 Most Influential Clinical Executives
        • Best Places to Work in Healthcare
        • Excellence in Governance
        • Health Care Hall of Fame
        • Healthcare Marketing Impact Awards
        • Top 25 Emerging Leaders
        • Top Innovators
        • Diversity in Healthcare
          • - Luminaries
          • - Top 25 Diversity Leaders
          • - Leaders to Watch
        • Women in Healthcare
          • - Luminaries
          • - Top 25 Women Leaders
          • - Women to Watch
      • Conferences
        • Digital Health Transformation Summit
        • ESG: The Implementation Imperative Summit
        • Leadership Symposium
        • Social Determinants of Health Symposium
        • Women Leaders in Healthcare Conference
      • Galas
        • Best Places to Work Awards Gala
        • Health Care Hall of Fame Gala
        • Top 25 Diversity Leaders Gala
        • Top 25 Women Leaders Gala
      • Virtual Briefings
        • - Hospital of the Future
        • - Value Based Care
        • - Hospital at Home
        • - Workplace of the Future
        • - AI and Digital Health
        • - Future of Staffing
        • - Hospital of the Future (Fall)
      • Webinars
    • Multimedia
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Sponsored Video Series - One on One
      • Sponsored Video Series - Checking In with Dan Peres
    • Data & Insights
      • Data & Insights Home
      • Hospital Financials
      • Staffing & Compensation
      • Quality & Safety
      • Mergers & Acquisitions
      • Data Archive
      • Resource Guide: By the Numbers
      • Surveys
      • Data Points
    • Newsletters
    • MORE+
      • Contact Us
      • Advertise
      • Media Kit
      • Jobs
      • People on the Move
      • Reprints & Licensing